1. the drug evaluated in the study, butylphthalide, is a national class I new drug developed independently by the Chinese, initially extracted from celery seeds, which can now be synthesized chemically. the drug was approved by the State Food and Drug Administration (SFDA) in February 2005 for the treatment of acute ischemic stroke and has been widely used clinically. it was later found to have a therapeutic effect on vascular cognitive impairment as well, but it has not been However, it has not been validated in large scale multicenter clinical trials. 2. Patients with non-demented vascular cognitive impairment are at high risk of progression to dementia, but there is no effective treatment for this disease. Our trial is the first international multicenter clinical trial for patients with non-demented vascular cognitive impairment. The subject enrollment criteria, outcome indicators, trial length, and drug effect size of this trial are enlightening and informative for subsequent clinical trials. 3. The study trial design was rigorous and corrected some problems that existed in previous clinical trials in this field: (1) Non-dementia vascular cognitive impairment is a syndrome that includes different etiological subtypes. Inclusion of patients with non-dementia vascular cognitive impairment in a generalized manner without differentiation of etiologic subtypes would result in a high degree of heterogeneity in the enrolled patients and would not be conducive to the assessment of true drug efficacy. The unique feature of our trial is the targeted selection of the subtype of subcortical non-dementia vascular cognitive impairment, thus overcoming the heterogeneity of the sample, which is the first of its kind internationally. (2) We developed more stringent imaging enrollment criteria than previous clinical trials, with all enrolled patients required to undergo a cranial MRI. This increases the sensitivity and specificity of the diagnosis of subcortical non-dementia vascular cognitive impairment and also excludes the effect of concomitant Alzheimer’s disease. 4. No drug has been found internationally to be effective for subcortical non-dementia vascular cognitive disorder, and our results confirm for the first time that a drug is effective for this disorder.